The BLA seeking accelerated approval for patritumab deruxtecan in previously treated, locally advanced EGFR-mutated NSCLC in ...

Patritumab deruxtecan was unable to significantly improve overall survival in patients with locally advanced or metastatic ...

A phase II study of atezolizumab combined with cisplatin and vinorelbine as adjuvant therapy for completely resected non-small cell lung cancer with EGFR mutation (WJOG11719L: ADJUST study).

Summit Therapeutics' recent stock sell-off reflects regulatory uncertainty rather than drug failure. Click here to read an ...

Rahway: Daiichi Sankyo and Merck, known as MSD outside of the United States and Canada, have announced that the Biologics ...

Dana-Farber Cancer Institute investigators launch a first-of-its kind study to use a novel blood test to identify people who ...

(SMMT) stock rises as its lung cancer drug ivonescimab with chemotherapy hit the main goal in a Phase 3 trial for lung cancer ...

Merck and Japan-based Daiichi Sankyo have withdrawn their U.S. application for an experimental lung cancer treatment after it ...

Lung cancer is the leading cause of cancer death in Western Australia, and is also the most common and one of the least ...

Ivonescimab helped cut the risk of lung tumor progression in half in a multi-country Phase 3 trial. But it hasn’t yet clearly ...

Among the lung cancer population with EGFR mutations, patients with insertions at exon 20 (ex20ins) represent a significant unmet need segment. These patients often have poorer outcomes compared to ...

(Alliance News) - Hutchmed China Ltd on Monday said its combination therapy for a specific form of advanced lung cancer significantly delayed disease progression compared to chemotherapy, based on ...